Packaging products producer Clondalkin Group has invested in booklet-label manufacturing and finishing equipment at its Glasnevin site in Ireland, in a bid to drive the development of clinical trial packaging standards.
According to the company, the site, which is part of its Specialist Packaging Division, invested in the Prati Vega booklet-label machine to bolster its offer of exacting compliance and quality performance across multiple study profiles.
Clondalkin Pharma & Healthcare Glasnevin site director Barry Marron said each booklet-label the company manufactures for its clinical trial customers will undergo up to 15 separate checks.
"Our site is extensively equipped in all stages of the print and production processes from origination and print through to conversion and delivery, and this investment represents our continued commitment to improve our processes, expand our capabilities and increase our flexibility," Marron said.
The increased capacity is expected to enable shorter lead times and better reliability for the company's international customer base in the clinical trials sector.
Producing booklets of up to 64 page counts, the Vega machine features an in-line lamination unit with register control, enabling the application of Braille in register to the outer laminate.
The system also incorporates a hot melt coating unit and pharma code scanning.
Clondalkin also installed two complete finishing lines equipped with inline ink jet coding and full vision inspection in order to increase the investment potential.
